Treatment-naive patients with HCV genotype @ infection were assigned randomly to @ of thefollowing groups : PEG-IFN/RBV for @ weeks ( group A , n = @ ) , PEG-IFN/RBV for @ weeks followed by PEG-IFN/RBV for @ weeks with @ injections of TG@ ( group B , n = @ ) , or TG@ for @ weeks ( @ injections ) followed by PEG-IFN/RBV for @ weeks with @ injections of TG@ ( group C , n = @ ) .